Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597455 | 0.87 | CYP4F2 (0.42) | F2KDM4ELMNAPPARDPPARG | |
| SCHEMBL5572663 | 0.85 | P2RX3 (0.44) | F2SRD5A2P2RX3PPARDPPARG | |
| SCHEMBL5575510 | 0.84 | PTGDR2 (0.46) | KDM4EEGLN1 | |
| SCHEMBL13809924 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL13809922 | 0.82 | F2 (0.46) | F2SRD5A2HSD11B1PTGS1AKR1C3 | |
| SCHEMBL3980466 | 0.82 | TDP1 (0.44) | F2SRD5A2KDM4EPPARG | |
| SCHEMBL4140304 | 0.80 | KDM4E (0.46) | KDM4ELMNA | |
| SCHEMBL4001831 | 0.79 | AR (0.43) | F2SRD5A2HSD11B1PTGS1AKR1C3 | |
| SCHEMBL5572824 | 0.78 | KDM4E (0.43) | KDM4ELMNA | |
| SCHEMBL4598347 | 0.78 | ALDH1A1 (0.50) | KDM4ELMNAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009075960-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075960-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | F2 4707/4885SRD5A2 2524/4885HSD11B1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.